RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
OncoTherapy Science Stock

OncoTherapy Science Revenue 2024

OncoTherapy Science Revenue

610.12 M JPY

Ticker

4564.T

ISIN

JP3202150003

WKN

726692

In 2024, OncoTherapy Science's sales reached 610.12 M JPY, a -46.24% difference from the 1.13 B JPY sales recorded in the previous year.

The OncoTherapy Science Revenue history

YEARREVENUE (undefined JPY)GROSS MARGIN (%)
20240.61-29,13
20231.133,67
20221.159,87
20210.335,88
20200.32-15,85
20190.28-63,34
20180.21-84,13
20170.29-61,99
20160.27-66,59
20150.77-23,08
20141.02-17,46
20133.28-5,42
20126.2224,24
20115.3611,35
20105.2612,94
20093.339,56
20081.97-3,87
20070.8-132,77
20061.16-51,89
20051.5828,15

OncoTherapy Science Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into OncoTherapy Science, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by OncoTherapy Science from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects OncoTherapy Science’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of OncoTherapy Science. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into OncoTherapy Science’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing OncoTherapy Science’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on OncoTherapy Science’s growth potential.

OncoTherapy Science Revenue, EBIT and net profit per share

DateOncoTherapy Science RevenueOncoTherapy Science EBITOncoTherapy Science Net Income
2024610.12 M JPY-1.12 B JPY-1.29 B JPY
20231.13 B JPY-1.11 B JPY-1.12 B JPY
20221.15 B JPY-2.05 B JPY-2.57 B JPY
2021332.48 M JPY-1.64 B JPY-1.56 B JPY
2020316.22 M JPY-2.19 B JPY-2.24 B JPY
2019280.59 M JPY-2.95 B JPY-2.93 B JPY
2018211.25 M JPY-2.99 B JPY-2.85 B JPY
2017286.67 M JPY-3 B JPY-3 B JPY
2016266.9 M JPY-2.98 B JPY-2.79 B JPY
2015769.96 M JPY-1.96 B JPY-1.33 B JPY
20141.02 B JPY-3.79 B JPY-3.68 B JPY
20133.28 B JPY-1.11 B JPY-1.1 B JPY
20126.22 B JPY1.18 B JPY727 M JPY
20115.36 B JPY223.3 M JPY566.8 M JPY
20105.26 B JPY332 M JPY510.2 M JPY
20093.33 B JPY40.6 M JPY148.2 M JPY
20081.97 B JPY-378.8 M JPY-202.1 M JPY
2007804.5 M JPY-1.35 B JPY-1.32 B JPY
20061.16 B JPY-833.4 M JPY-525.7 M JPY
20051.58 B JPY35.1 M JPY17.4 M JPY

OncoTherapy Science stock margins

The OncoTherapy Science margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OncoTherapy Science. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OncoTherapy Science.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the OncoTherapy Science's sales revenue. A higher gross margin percentage indicates that the OncoTherapy Science retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the OncoTherapy Science's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the OncoTherapy Science's total revenue generated. When comparing the revenue margin year over year, investors can gauge the OncoTherapy Science's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the OncoTherapy Science. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the OncoTherapy Science's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

OncoTherapy Science Margin History

OncoTherapy Science Gross marginOncoTherapy Science Profit marginOncoTherapy Science EBIT marginOncoTherapy Science Profit margin
2024-29.13 %-183.7 %-211.13 %
20233.67 %-97.49 %-98.57 %
20229.87 %-177.92 %-222.9 %
20215.88 %-492.65 %-469.7 %
2020-15.85 %-692.46 %-707.92 %
2019-29.13 %-1,052.72 %-1,046.01 %
2018-29.13 %-1,414.71 %-1,349.62 %
2017-29.13 %-1,047.98 %-1,047.23 %
2016-29.13 %-1,116.85 %-1,044.88 %
2015-29.13 %-254.88 %-173.37 %
2014-29.13 %-371.97 %-361.23 %
2013-29.13 %-33.98 %-33.66 %
201224.24 %19.03 %11.68 %
201111.35 %4.16 %10.57 %
201012.94 %6.31 %9.7 %
20099.56 %1.22 %4.45 %
2008-3.87 %-19.2 %-10.24 %
2007-132.77 %-167.64 %-164.5 %
2006-51.89 %-71.55 %-45.13 %
200528.15 %2.22 %1.1 %

OncoTherapy Science Aktienanalyse

What does OncoTherapy Science do?

OncoTherapy Science Inc is a rising company that focuses on the research and development of novel cancer therapies. The company takes pride in being able to combine the latest scientific findings with cutting-edge technologies to develop highly effective drugs and therapies that can improve the lives of cancer patients. The company is based in Japan and was founded in 2001. Since its inception, it has become one of the leading companies in cancer research and its products are available worldwide. OncoTherapy Science Inc's business model is based on the development and commercialization of new innovative cancer therapies. The company utilizes the latest technologies and research findings to achieve groundbreaking advancements in cancer treatment. These innovative therapies have the potential to improve the survival and quality of life of cancer patients. OncoTherapy Science Inc divides its activities into various areas. This includes the research and development of drugs, the clinical testing of new therapies, and the production and commercialization of cancer therapies. The research and development of new drugs form the core of OncoTherapy Science Inc's activities. The company continuously invests in researching new treatment approaches to improve the effectiveness and safety of cancer therapies. Advanced technologies such as genome sequencing and molecular diagnostics are utilized to develop personalized therapies tailored to specific types of cancer and patients. OncoTherapy Science Inc also conducts extensive clinical trials to evaluate the effectiveness and safety of its therapies. The success rate of clinical studies is very high, and many of the therapies have already received approval from regulatory authorities. Another important area of OncoTherapy Science Inc is the production and commercialization of cancer therapies. The company works closely with its distribution partners to ensure that its products are available in many countries and regions. OncoTherapy Science Inc's therapies are recommended by many oncologists and used in leading clinical institutions worldwide. Products of OncoTherapy Science Inc include a range of innovative cancer therapies. These include antibody-based drugs, immunotherapies, RNA-based therapies, and chemotherapy. These therapies have the potential to improve the effectiveness of cancer treatment and enhance the quality of life of cancer patients. An example of an innovative therapy by OncoTherapy Science Inc is OTS964, a new chemotherapeutic agent for the treatment of pancreatic cancer and other cancers. OTS964 inhibits the enzyme TOPK, which is overexpressed in many types of cancer, leading to the death of cancer cells. This therapy has shown promising results in animal models and is currently being tested in clinical trials. OncoTherapy Science Inc aims to contribute to improving the quality of life of cancer patients. The company relies on a combination of innovative research, state-of-the-art technology, and close collaboration with other industry stakeholders to achieve a leading position in cancer research. With its strong market position and commitment to cancer research, OncoTherapy Science Inc is a company that will achieve much in the future. OncoTherapy Science ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding OncoTherapy Science's Sales Figures

The sales figures of OncoTherapy Science originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing OncoTherapy Science’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize OncoTherapy Science's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in OncoTherapy Science’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about OncoTherapy Science stock

How much revenue did OncoTherapy Science generate this year?

OncoTherapy Science has achieved a revenue of 610.12 M JPY this year.

How much was the turnover of the company OncoTherapy Science compared to the previous year?

The revenue of OncoTherapy Science has increased by -46.24% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of OncoTherapy Science?

The revenue of OncoTherapy Science is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of OncoTherapy Science measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of OncoTherapy Science so important for investors?

The revenue of OncoTherapy Science is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does OncoTherapy Science pay?

Over the past 12 months, OncoTherapy Science paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OncoTherapy Science is expected to pay a dividend of 0 JPY.

What is the dividend yield of OncoTherapy Science?

The current dividend yield of OncoTherapy Science is .

When does OncoTherapy Science pay dividends?

OncoTherapy Science pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of OncoTherapy Science?

OncoTherapy Science paid dividends every year for the past 0 years.

What is the dividend of OncoTherapy Science?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is OncoTherapy Science located?

OncoTherapy Science is assigned to the 'Health' sector.

Wann musste ich die Aktien von OncoTherapy Science kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of OncoTherapy Science from 9/30/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did OncoTherapy Science pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of OncoTherapy Science in the year 2023?

In the year 2023, OncoTherapy Science distributed 0 JPY as dividends.

In which currency does OncoTherapy Science pay out the dividend?

The dividends of OncoTherapy Science are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von OncoTherapy Science

Our stock analysis for OncoTherapy Science Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoTherapy Science Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.